Robert J Cerfolio1, Asem F Ghanim2, Mark Dylewski3, Giulia Veronesi4, Lorenzo Spaggiari5, Bernard J Park6. 1. Division of Thoracic Surgery, University of Alabama - Birmingham, Birmingham, Ala. Electronic address: robert.cerfolio@nyu.org. 2. Division of Thoracic Surgery, University of Alabama - Birmingham, Birmingham, Ala. 3. Division of Thoracic Surgery, Baptist Health of South Florida, Miami, Fla. 4. Division of Thoracic Surgery, Istituto Clinico Humanitas Cancer Center, Rozzano, Milan, Italy; Istituto Europeo Di Oncologia, Milan, Italy. 5. Istituto Europeo Di Oncologia, Milan, Italy. 6. Thoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY.
Abstract
OBJECTIVE: Our objective is to report the world's largest series with the longest follow-up of robotic lobectomy for non-small cell lung cancer (NSCLC). METHODS: This was a multi-institutional retrospective review of a consecutive series of patients from 4 institutions' prospective robotic databases. RESULTS: There were 1339 patients (men 55%, median age 68 years). The median operative time was 136 minutes, median number of lymph nodes was 13 (5 N2 stations and 1 N1), median blood loss was 50 cc, and 4 (0.005%) patients received intraoperative transfusions. Conversions occurred in 116 patients (9%) and for bleeding in 24 (2%). Median length of stay was 3 days. Major morbidity occurred in 8%. The 30-day and 90-day operative mortality was 0.2% and 0.5%, respectively. Follow-up was complete in 99% of patients with a median follow-up of 30 months (range 1-154 months). The 5-year stage-specific survival was: 83% for the 672 patients with stage IA NSCLC, 77% for the 281 patients with stage IB, 68% for the 118 patients with stage IIA, 70% for 99 patients with IIB, 62% for 143 patients with stage IIIA (122 had N2 disease, 73%), and 31% for 8 patients with stage IIIB (none had N3 disease). The cumulative incidence of metastatic NSCLC was 15% (128 patients, 95% confidence interval, 13%-18%). The cumulative incidence of local recurrence in the ipsilateral operated chest was 3% only (26 patients, 95% confidence interval, 2%-5%). CONCLUSIONS: The oncologic results of robotic lobectomy for NSCLC are promising, especially for patients with pathologic N2 disease. However, further follow-up and studies are needed.
OBJECTIVE: Our objective is to report the world's largest series with the longest follow-up of robotic lobectomy for non-small cell lung cancer (NSCLC). METHODS: This was a multi-institutional retrospective review of a consecutive series of patients from 4 institutions' prospective robotic databases. RESULTS: There were 1339 patients (men 55%, median age 68 years). The median operative time was 136 minutes, median number of lymph nodes was 13 (5 N2 stations and 1 N1), median blood loss was 50 cc, and 4 (0.005%) patients received intraoperative transfusions. Conversions occurred in 116 patients (9%) and for bleeding in 24 (2%). Median length of stay was 3 days. Major morbidity occurred in 8%. The 30-day and 90-day operative mortality was 0.2% and 0.5%, respectively. Follow-up was complete in 99% of patients with a median follow-up of 30 months (range 1-154 months). The 5-year stage-specific survival was: 83% for the 672 patients with stage IA NSCLC, 77% for the 281 patients with stage IB, 68% for the 118 patients with stage IIA, 70% for 99 patients with IIB, 62% for 143 patients with stage IIIA (122 had N2 disease, 73%), and 31% for 8 patients with stage IIIB (none had N3 disease). The cumulative incidence of metastatic NSCLC was 15% (128 patients, 95% confidence interval, 13%-18%). The cumulative incidence of local recurrence in the ipsilateral operated chest was 3% only (26 patients, 95% confidence interval, 2%-5%). CONCLUSIONS: The oncologic results of robotic lobectomy for NSCLC are promising, especially for patients with pathologic N2 disease. However, further follow-up and studies are needed.
Authors: Raja M Flores; Ugonna N Ihekweazu; Nabil Rizk; Joseph Dycoco; Manjit S Bains; Robert J Downey; Prasad Adusumilli; David J Finley; James Huang; Valerie W Rusch; Inderpal Sarkaria; Bernard Park Journal: J Thorac Cardiovasc Surg Date: 2010-11-05 Impact factor: 5.209
Authors: Ravi Rajaram; Sanjay Mohanty; David J Bentrem; Emily S Pavey; David D Odell; Ankit Bharat; Karl Y Bilimoria; Malcolm M DeCamp Journal: Ann Thorac Surg Date: 2017-01-18 Impact factor: 4.330
Authors: Raja M Flores; Bernard J Park; Joseph Dycoco; Anna Aronova; Yael Hirth; Nabil P Rizk; Manjit Bains; Robert J Downey; Valerie W Rusch Journal: J Thorac Cardiovasc Surg Date: 2009-07 Impact factor: 5.209
Authors: Paul C Lee; Abu Nasar; Jeffrey L Port; Subroto Paul; Brendon Stiles; Ya-Lin Chiu; Weston G Andrews; Nasser K Altorki Journal: Ann Thorac Surg Date: 2013-07-16 Impact factor: 4.330
Authors: Henri Gondé; Constance Le Gac; André Gillibert; Benjamin Bottet; Marc Laurent; Matthieu Sarsam; Charles Hervouët; Rémi Varin; Jean-Marc Baste Journal: J Thorac Dis Date: 2019-07 Impact factor: 2.895